BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology

Bispecific T-Cell Engagers (BiTEs) are effective at inducing remission in hematologic cancers, but their use in solid tumors has been challenging due to their extreme potency and on-target, off-tumor toxicities in healthy tissue. Their deployment against solid tumors is further complicated by insuff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, S., Inamdar, V.V., Sigmund, E.C., Zhang, F., Stephan, S.B., Watson, C., Weaver, S.J., Nielsen, U.B., Stephan, M.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840964/
https://www.ncbi.nlm.nih.gov/pubmed/34953983
http://dx.doi.org/10.1016/j.jconrel.2021.12.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840964/
https://www.ncbi.nlm.nih.gov/pubmed/34953983
http://dx.doi.org/10.1016/j.jconrel.2021.12.029

Ejemplares similares